← Back to Search

Other

RCT treatment arm for Urinary Tract Infection

Phase 2 & 3
Waitlist Available
Led By Jerry Lowder, MD
Research Sponsored by Washington University School of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up each participant will be followed for 90 days during study enrollment
Awards & highlights

Study Summary

This trial will study whether a nutraceutical can prevent recurrent urinary tract infections in post-menopausal women, with and without vaginal estrogen therapy.

Eligible Conditions
  • Urinary Tract Infection

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~each participant will be followed for 90 days during study enrollment
This trial's timeline: 3 weeks for screening, Varies for treatment, and each participant will be followed for 90 days during study enrollment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Urinary tract infection
Secondary outcome measures
Urinary tract infection
Incidence of Symptomatic, Culture Proven UTI in All Participants Taking D-mannose
Side Effects

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: RCT treatment armExperimental Treatment1 Intervention
Participants in this arm will dissolve one (1) level teaspoon of the nutraceutical powder (D-mannose) in at least 200 ml of water one time a day, approximately every 24 hours. (200 ml of water = 6.7 fluid ounces). Duration of study drug is 90 days.
Group II: Observational armExperimental Treatment1 Intervention
Participants in this arm will either take a total of 1000 mg D-mannose in capsule form every 12 hours OR they will dissolve one (1) level teaspoon of the nutraceutical powder (D-mannose) in at least 200 ml of water one time a day, approximately every 24 hours. (200 ml of water = 6.7 fluid ounces). Duration of study drug is 90 days. Participants in this arm of the study have different home medications prior to study enrollment than participants in the RCT treatment arm.
Group III: RCT control armActive Control1 Intervention
Participants in this arm will not use any additional intervention.

Find a Location

Who is running the clinical trial?

Washington University School of MedicineLead Sponsor
1,949 Previous Clinical Trials
2,307,536 Total Patients Enrolled
1 Trials studying Urinary Tract Infection
Jerry Lowder, MDPrincipal InvestigatorWashington University School of Medicine
1 Previous Clinical Trials
386 Total Patients Enrolled
~8 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top